Refractory lupus nephritis, broadly defined as failure to attain clinical remission after
appropriate induction immunosuppressive therapy, is associated with an increased risk of …

Systemic lupus erythematosus (SLE) represents a diagnostic and therapeutic challenge for
physicians due to its protean manifestations and unpredictable course. The disease may …

Objective The British Isles Lupus Assessment Group–based Composite Lupus Assessment
(BICLA) is a validated global measure of treatment response in systemic lupus …

CD22, a sialic acid–binding Ig-type lectin (Siglec) family member, is an inhibitory coreceptor
of the BCR with established roles in health and disease. The restricted expression pattern of …

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune systemic disease with a wide
range of clinical symptoms, complex development processes, and uncertain prognosis. The …

Simple Summary Sialic acid dysregulation is closely associated with the occurrence and
development of tumors. Sialic acid-binding immunoglobulin-like lectins (Siglecs) are a class …

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease involving multiple
systems with a range of clinical presentations caused by the production of antibodies …

The advent of targeted biologic therapy has had a dramatic impact in the treatment of a wide
variety of diseases including immune-mediated inflammatory diseases, cancer, allergy, and …

Systemic Lupus Erythematosus (SLE) is a chronic systemic autoimmune disease of high
clinical and molecular heterogeneity, and a relapsing-remitting pattern. The disease is …

Introduction Systemic lupus erythematosus (SLE) is characterized by autoantibody
expression and aberrant autoreactive B cells contribute to disease progression; therefore, B …